![Isabel Gomez de Coppel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Isabel Gomez de Coppel
Director/Miembro de la Junta en NeuroCytonix, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
J. Trujillo | M | - |
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | 7 años |
Laurent Lavigne du Cadet | M | - |
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | - |
Jeffrey Balagna | M | 63 |
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | - |
Michael Batt | M | - |
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | - |
Armando Requejo | M | - |
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 5 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Isabel Gomez de Coppel
- Red Personal